Qiagen N.V. (NYSE:QGEN) Receives $52.84 Consensus Price Target from Brokerages

Qiagen N.V. (NYSE:QGEN) has received a consensus recommendation of “Hold” from the eight analysts that are covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $52.8421.

QGEN has been the topic of several research reports. Citigroup lowered Qiagen from a “buy” rating to a “neutral” rating and cut their price target for the company from $57.89 to $52.63 in a research note on Thursday, December 11th. Weiss Ratings reiterated a “hold (c)” rating on shares of Qiagen in a report on Monday, December 29th. Wall Street Zen lowered Qiagen from a “buy” rating to a “hold” rating in a research report on Saturday, January 10th. UBS Group reaffirmed a “neutral” rating on shares of Qiagen in a report on Wednesday. Finally, Barclays reaffirmed an “overweight” rating and issued a $57.89 price objective (up from $55.79) on shares of Qiagen in a research report on Monday, December 15th.

Qiagen Price Performance

Qiagen stock opened at $55.55 on Monday. The company has a debt-to-equity ratio of 0.45, a current ratio of 2.60 and a quick ratio of 2.30. The stock has a market cap of $11.73 billion, a price-to-earnings ratio of 28.68, a price-to-earnings-growth ratio of 2.55 and a beta of 0.66. The firm has a 50-day moving average of $48.56 and a two-hundred day moving average of $49.45. Qiagen has a 1 year low of $39.61 and a 1 year high of $57.81.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.61 by $0.03. Qiagen had a net margin of 19.58% and a return on equity of 14.80%. The firm had revenue of $532.58 million during the quarter, compared to the consensus estimate of $525.68 million. During the same quarter in the previous year, the firm posted $0.60 earnings per share. The company’s revenue was up 6.2% on a year-over-year basis. On average, research analysts forecast that Qiagen will post 2.26 earnings per share for the current year.

Institutional Trading of Qiagen

Several large investors have recently added to or reduced their stakes in the company. Danske Bank A S purchased a new position in shares of Qiagen in the third quarter worth about $36,000. Smartleaf Asset Management LLC boosted its holdings in shares of Qiagen by 1,383.3% in the 3rd quarter. Smartleaf Asset Management LLC now owns 890 shares of the company’s stock valued at $39,000 after acquiring an additional 830 shares during the last quarter. MAI Capital Management increased its stake in shares of Qiagen by 998.9% in the second quarter. MAI Capital Management now owns 978 shares of the company’s stock worth $47,000 after acquiring an additional 889 shares during the period. Farther Finance Advisors LLC raised its holdings in shares of Qiagen by 400.5% during the second quarter. Farther Finance Advisors LLC now owns 1,061 shares of the company’s stock worth $51,000 after purchasing an additional 849 shares during the last quarter. Finally, Allworth Financial LP lifted its position in Qiagen by 260.1% during the second quarter. Allworth Financial LP now owns 1,102 shares of the company’s stock valued at $53,000 after purchasing an additional 796 shares during the period. Hedge funds and other institutional investors own 70.00% of the company’s stock.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.